Celldex Q4 revenue falls

Celldex Therapeutics

25/02/2026 21:13

Overview

Biotech firm's Q4 revenue fell yr/yr

Net loss for Q4 exceeded analyst estimates

Outlook

Celldex anticipates topline data from Phase 3 CSU studies in Q4 2026

Company expects Phase 2 prurigo nodularis data in summer 2026

Result Drivers

R&D Expenses - Research and development expenses were $75.3 million in the fourth quarter of 2025

Company press release: ID:nGNX46ZlBw

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
$121,000
Q4 EPS
Miss
-$1.22
-$1.009 (14 Analysts)
Q4 Net Income
-$81.32 mln
-$68.13 mln (9 Analysts)
Q4 Operating Expenses
$87.27 mln
Q4 Operating Income
-$87.15 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Celldex Therapeutics Inc is $48.00, about 93.2% above its February 24 closing price of $24.84

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)